Combinations with a backbone-cyclized peptide
A novel combination comprising a β-hairpin peptidomimetic of the formula cyclo(-Thr-Trp-Ile-Dab-Orn- D Dab-Dab-Trp-Dab-Dab-Ala-Ser- D Pro-Pro) (I), and a further compound with antibiotic activity, that enable therapeutic control of specific bacterial infections in human or animals at doses of the individual compounds lower than either of the compounds administered alone. The combination can be used as a medicament to treat e.g. skin or soft tissue infections; eye, ear, blood stream, or intra-abdominal infections; infections related to respiratory diseases, to bone diseases, to cardiovascular diseases, to genitourinal diseases, or to gastrointestinal diseases.
1. A combination comprising a β-hairpin peptidomimetic of the formula cyclo(-Thr-Trp-Ile-Dab-Orn- D Dab-Dab-Trp-Dab-Dab-Ala-Ser- D Pro-Pro) (I),
wherein
Dab is (S)-2,4-diaminobutanoic acid;
D Dab is (R)-2,4-diaminobutanoic acid;
Orn is (S)-2,5-diaminopentanoic acid;
and
a further antibiotic compound selected from ciprofloxacin, levofloxacin, moxifloxacin, gemifloxacin, ceftaroline, ceftobiprole, ceftazidime, ceftriaxone, cefepime, daptomycin, ramoplanin, vancomycin, colistin, polymyxin B, ertapenem, meropenem, doripenem, imipenem, aztreonam, piperacillin, amikacin, rifampicin, neomycin, gentamicin, tobramycin, fosfomycin, azithromycin, minocycline, doxycycline, or tetracycline,
or a pharmaceutically acceptable salt thereof.
2. The combination according to claim 1 wherein the further antibiotic compound is selected from ertapenem, azithromycin, ciprofloxacin, or amikacin, or a pharma-ceutically acceptable salt thereof.
3. The combination according to claim 1 wherein the further antibiotic compound is selected from the class of macrolides, or pharmaceutically acceptable salts thereof.
4. The combination according to claim 1 wherein the further antibiotic compound is selected from the class of quinolones, or pharmaceutically acceptable salts thereof.
5. The combination according to claim 1 wherein the further antibiotic compound is selected from the class of aminoglycosides, or pharmaceutically acceptable salts thereof.
6. The combination according to claim 1 wherein the further antibiotic compound is ertapenem, or a pharmaceutically acceptable salt thereof.
7. The combination according to claim 1 wherein the further antibiotic compound is azithromycin, or a pharmaceutically acceptable salt thereof.
8. The combination according to claim 1 wherein the further antibiotic compound is ciprofloxacin, or a pharmaceutically acceptable salt thereof.
9. The combination according to claim 1 wherein the further antibiotic compound is amikacin, or a pharmaceutically acceptable salt thereof.
10. The combination according to claim 1 for use in medicine.
11. The combination according to claim 1 for the treatment of bacterial infections or diseases related to such infections in human or animals.
12. A method for manufacturing a pharmaceutical compositing comprising the combination according to claim 1 , comprising:
formulating the pharmaceutical composition for the treatment of bacterial infections or diseases related to such infections in human or animals.
13. A pharmaceutical composition containing a combination according to claim 1 and at least one pharmaceutically inert carrier.
14. The pharmaceutical composition according to claim 13 in a form suitable for oral, topical, transdermal, injection, infusion, buccal, transmucosal, rectal, vaginal, pulmonary or inhalation administration, especially in the form of tablets, dragees, capsules, solutions, liquids, gels, plaster, creams, ointments, syrup, slurries, powders, suspensions, spray, nebulizer or suppositories.
15. A method for the treatment of bacterial infections or diseases related to such infections in a human or an animal, comprising:
administering a therapeutically effective amount of the pharmaceutical composition according to claim 13 to the human or the animal.
16. A kit comprising a part containing a β-hairpin peptidomimetic of the formula (I) according to claim 1 , or a pharmaceutically acceptable salt thereof.
17. A kit comprising a part containing a β-hairpin peptidomimetic of the formula (I) according to claim 1 , or a pharmaceutically acceptable salt thereof and a part containing a compound with antibiotic activity selected from the classes of β-lactams, carbapenems, macrolides, quinolones, or aminoglycosides, or pharmaceutically acceptable salts thereof.
18. A kit according to claim 16 wherein the compound with antibiotic activity is selected from ertapenem, meropenem, azithromycin, ciprofloxacin, amikacin, neomycin, tobramycin, colistin, polymyxin B, minocycline, or tetracycline,
or a pharmaceutically acceptable salt thereof.
19. A kit according to claim 16 wherein the compound with antibiotic activity is selected from ertapenem, azithromycin, ciprofloxacin, or amikacin, or a pharmaceutically acceptable salt thereof.
20. A kit according to claim 16 wherein the compound with antibiotic activity is ertapenem, or a pharmaceutically acceptable salt thereof.
21. A kit according to claim 16 wherein the compound with antibiotic activity is azithromycin, or a pharmaceutically acceptable salt thereof.
22. A kit according to claim 16 wherein the compound with antibiotic activity is ciprofloxacin, or a pharmaceutically acceptable salt thereof.
23. A kit according to claim 16 wherein the compound with antibiotic activity is amikacin AG , or a pharmaceutically acceptable salt thereof.
24. A method of treating an bacterial infection or disease related to such infection in human or animals comprising administering to a subject in need thereof an adequate amount of a combination according to claim 1 .